Citius Pharmaceuticals’ (CTXR) “Buy” Rating Reiterated at D. Boral Capital
D. Boral Capital reiterated their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR – Free Report) in a research note published on Thursday morning,Benzinga reports. D. Boral Capital currently has a $9.00 price objective on the stock. Citius Pharmaceuticals Trading Up 2.5% NASDAQ CTXR opened at $0.85 on Thursday. Citius Pharmaceuticals has a 12 month […]
D. Boral Capital reiterated their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR – Free Report) in a research note published on Thursday morning,Benzinga reports. D. Boral Capital currently has a $9.00 price objective on the stock. Citius Pharmaceuticals Trading Up 2.5% NASDAQ CTXR opened at $0.85 on Thursday. Citius Pharmaceuticals has a 12 month […]
